Correction to: Outcomes of endoscopic treatment for malignant biliary obstruction in patients with surgically altered anatomy: analysis of risk factors for clinical failure

Takeshi Tomoda¹ · Hironari Kato¹ · Kazuya Miyamoto¹ · Akihiro Matsumi¹ · Eijiro Ueta¹ · Yuuki Fujii¹ · Yousuke Saragai¹ · Tatsuhiro Yamazaki¹ · Daisuke Uchida¹ · Kazuyuki Matsumoto¹ · Shigeru Horiguchi¹ · Koichiro Tsutsumi¹ · Hiroyuki Okada¹

Published online: 6 February 2020
© Springer Science+Business Media, LLC, part of Springer Nature 2020

Correction to: Surgical Endoscopy
<https://doi.org/10.1007/s00464-020-07385-y>

There are several places where the P-value and Odds ratio in Table 3 are incorrect: these are shown in the corrected Table 3.

The following two sentences related to Table 3 should be corrected:

1. In the Results section of the Abstract, the sentence

“In multivariate analysis, the presence of peritoneal dissemination (odds ratio, 7.3; 95% confidence interval, 1.5–43.5, $p = 0.02$) was as an independent risk factor for clinical failure.”

should read:

“In multivariate analysis, the presence of peritoneal dissemination (odds ratio, 6.8; 95% confidence interval,

1.6–32.8, $p = 0.008$) was as an independent risk factor for clinical failure.”

2. In the last line of Clinical outcome section, the sentence

“In multivariate analysis, the presence of peritoneal dissemination (odds ratio, 7.3; 95% confidence interval, 1.5–43.5) ($p = 0.02$) was as an independent risk factor for clinical failure.”

should read:

“In multivariate analysis, the presence of peritoneal dissemination (odds ratio, 6.8; 95% confidence interval, 1.6–32.8) ($p = 0.008$) was as an independent risk factor for clinical failure.”

The authors regret these errors.

The original article can be found online at <https://doi.org/10.1007/s00464-020-07385-y>.

✉ Takeshi Tomoda
tomotake79@yahoo.co.jp

¹ Department of Gastroenterology and Hepatology,
Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku,
Okayama-city, Okayama 700-8558, Japan

Table 3 Risk factor for clinical failure via endoscopic treatment of MBO in patients with surgically altered anatomy

	Clinical failure <i>n</i> = 14	Clinical success <i>n</i> = 31	Univariate analysis			Multivariate analysis		
			OR	95% CI	<i>p</i> value	OR	95% CI	<i>p</i> value
Age, (> 67 years), <i>n</i> (%)	7 (50.0%)	16 (51.6%)	0.9	0.3–3.3	0.92			
Sex, male, <i>n</i> (%)	8 (57.1%)	21 (67.7%)	0.6	0.2–2.3	0.49			
Etiology of MBO, <i>n</i> (%)								
Malignant biliary disease	4 (28.6%)	12 (38.7%)	0.6	0.1–2.4	0.51			
Malignant pancreatic disease	3 (21.4%)	10 (32.3%)	0.6	0.1–2.3	0.45			
Gastric cancer	6 (42.9%)	6 (19.4%)	3.1	0.8–12.9	0.11			
Colon cancer	0 (0%)	3 (9.7%)	0		0.13			
Hepatocellular carcinoma	1 (7.1%)	0 (0%)	–		0.13			
Type of MBO, <i>n</i> (%)			0.9	0.2–7.0	0.90			
Primary disease	2 (14.3%)	4 (12.9%)						
Recurrent disease	12 (85.7%)	27 (87.1%)						
Liver metastasis	2 (14.3%)	10 (32.3%)						
Lymph node metastasis	3 (21.4%)	4 (12.9%)						
Local recurrence	7 (50.0%)	13 (41.9%)						
Location of MBO, <i>n</i> (%)			2.2	0.6–8.3	0.26			
Hilar or HJ anastomosis	8 (57.1%)	23 (74.2%)						
Distal	6 (42.9%)	8 (25.8%)						
Presence of peritoneal dissemination, <i>n</i> (%)	8 (57.1%)	5 (16.1%)	6.9	1.7–31.3	0.006	6.8	1.6–32.8	0.008
Digestive reconstruction, <i>n</i> (%)								
Modified child's method	3 (21.4%)	15 (48.4%)	0.3	0.1–1.1	0.08	0.3	0.1–1.3	0.12
RY gastrectomy	5 (35.7%)	8 (25.8%)	1.6	0.4–6.2	0.50			
RY hepaticojunostomy	4 (28.6%)	5 (16.1%)	2.1	0.4–9.5	0.34			
Billroth II with gastrectomy	2 (14.3%)	3 (9.7%)	1.6	0.2–10.6	0.66			
Presence of native papilla, <i>n</i> (%)	7 (50.0%)	11 (35.5%)	1.8	0.5–6.7	0.36			
Time from surgery to ERCP (> 505 days), <i>n</i> (%)	5 (35.7%)	18 (58.1%)	0.4	0.1–1.4	0.16			
T-Bil (> 2.5 mg/dL), <i>n</i> (%)	9 (64.3%)	13 (41.9%)	2.5	0.7–9.8	0.16			
AST (> 80 IU/L), <i>n</i> (%)	8 (57.1%)	14 (45.2%)	1.6	0.5–6.0	0.46			
ALT (> 72 IU/L), <i>n</i> (%)	8 (57.1%)	14 (45.2%)	1.6	0.5–6.0	0.46			
γGTP (> 364 IU/L), <i>n</i> (%)	8 (57.1%)	13 (41.9%)	1.8	0.5–6.9	0.34			
ALP (> 1205 IU/L), <i>n</i> (%)	6 (42.9%)	15 (48.4%)	0.8	0.2–2.8	0.73			
Type of scope, <i>n</i> (%)			1.5	0.4–7.8	0.59			
EI-580BT	3 (21.4%)	9 (29.0%)						
Other scope	11 (78.6%)	22 (71.0%)						

MBO malignant biliary obstruction, HJ hepaticojunostomy, RY Roux-en-Y, ERCP endoscopic retrograde cholangiopancreatography, TB total bilirubin, AST aspartate aminotransaminase, ALT alanine aminotransferase, γGTP g-glutamyl transpeptidase, ALP alkaline phosphatase, OR odds ratio, CI confidence interval

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.